Hyperuricemic PRP in Tendon Cells

Table 2

Relative gene expression normalised to the mean of GAPDH and TBP () given as medians and 25–75 percentiles.

Cell donor	SCX	HAS2	COLA1	COLA3	COMP	DCN	IL6	COX2	IL8	ACAN	TGF-b1
T1	0.073; (0.057–0.113)	1.308; (0.816–1.610)	158.67; (136.07–166.94)	7.052; (3.252–11.519)	0.025; (0.020–0.030)	2.256; (1.670–2.789)	0.166; (0.149–0.172)	0.088; (0.037–0.112)	0.045; (0.039–0.057)	0.0202; (0.0124–0.0342)	0.6676; (0.4728–1.3547)
T2	0.049; (0.035–0.068)	1.710; (1.493–2.232)	74.792; (40.05–113.63)	3.558; (2.831–5.468)	0.025; (0.023–0.038)	1.697; (1.444–2.216)	0.805; (0.481–1.254)	0.149; (0.117–0.227)	2.058; (1.885–2.480)	0.007; (0.006–0.008)	0.590; (0.504–0.676)
T3	0.005; (0.003–0.136)	2.055; (1.909–2.974)	137.16; (104.5–154.5)	1.517; (1.174–1.60)	2.003; (1.91–5.17)	0. 489; (0.419–0.854)	0.052; (0.032–0.076)	0.048; (0.045–0.343)	0.02; (0.016–0.159)	0.568; (0.172–0.812)	0.828; (0.616–10.98)

Relative expression levels of tendon cells from three donors (T1, T2, and T3) treated with allogeneic PRP (six donors) for 96 hours, normalised to the mean of GAPDH and TBP () given as medians and 25–75 percentiles.
Scleraxis (SCX), decorin (DCN), tenomodulin (TNMD), cartilage oligomeric protein (COMP), aggrecan (ACAN), SRY (sex determining region Y)-box 9 (SOX9), collagen type I alpha 1 (COL1A1), collagen type 3 alpha 1 (COL3A1), collagen type II alpha 1 (COL2A1), hyaluronan synthase 2 (HAS2), interleukin-1, beta (IL-1b), interleukin-6 (IL-6), interleukin-8 (IL-8), cytochrome c oxidase 1 (COX1), cytochrome c oxidase 2 (COX2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and TATA box binding protein (TBP).